Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Change in Acquisitions & Divestments (2019 - 2025)

Dianthus Therapeutics (DNTH) has 5 years of Change in Acquisitions & Divestments data on record, last reported at $78.6 million in Q3 2025.

  • For Q3 2025, Change in Acquisitions & Divestments rose 313.53% year-over-year to $78.6 million; the TTM value through Sep 2025 reached $305.3 million, up 408.86%, while the annual FY2024 figure was $127.0 million, 63.27% up from the prior year.
  • Change in Acquisitions & Divestments reached $78.6 million in Q3 2025 per DNTH's latest filing, up from $59.6 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $85.0 million in Q4 2024 and bottomed at $2.0 million in Q4 2022.
  • Average Change in Acquisitions & Divestments over 4 years is $35.6 million, with a median of $20.4 million recorded in 2023.
  • Peak YoY movement for Change in Acquisitions & Divestments: surged 800.0% in 2023, then tumbled 63.45% in 2024.
  • A 4-year view of Change in Acquisitions & Divestments shows it stood at $2.0 million in 2022, then soared by 800.0% to $18.0 million in 2023, then surged by 372.22% to $85.0 million in 2024, then dropped by 7.56% to $78.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $78.6 million in Q3 2025, $59.6 million in Q2 2025, and $82.1 million in Q1 2025.